Clinical Trials

1. Zoledronate with or without Thalidomide for Early Stage Multiple Myeloma (MC0289)
2. Study of IDEC-Y2B8 in the Treatment of Non-Hodgkin Lymphoma
3. Imaging Cells in Monoclonal Antibody Therapy for Lymphoma
4. Drug Therapy for the Treatment of Acute Myeloid Leukemia (AML)
5. A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia
6. C0701a/501, An Open-Label Extended-Use Study of Oral CEP-701 in Patients with Hematologic and Non-Hematologic Malignancies who have Completed a Clinical Study of CEP-701
7. AMD3100-CUP001, Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation
8. Zevalin Radionimmunotherapy with High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma (MC048A)
9. Genetic Epidemiology of B-Cell Lymphoproliferative Disorders
10. Daily Oral Polyphenon E in Asymptomatic Rai Stage 0-II Patients with Chronic Lymphocytic Leukemia (MC0419)
11. Study Evaluating Types of Iron and Combining with Darbopoetin Alfa (Aranesp) for Cancer Patients Experiencing Anemia
12. Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia
13. Immunosuppressant, Alefacept (Amevive), in the Treatment of Cutaneous T-Cell Lymphoma and Peripheral T-Cell Non-Hodgkin Lymphoma (LS058C)
14. Systemic Administration of (Edmonston Strain) of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide in Patients with Recurrent or Refractory Multiple Myeloma (MC038C)
15. Response-Adapted Therapy for Aggressive non-Hodgkin Lymphomas (NHL) based on early [18F] FDG-PET Scanning
16. A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib (Bay 43-9006) in Combination with the mTOR Inhibitor RAD001 (Everolimus, Certican) in Patients with Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma
17. A Phase I and Pharmacological Clinical Trial of 17-Allylamino-17-demethoxygeldanamycin (17-AAG) and Cytarabine (Ara-C) in Refractory (Resistent) Leukemia and Myelodysplastic Syndrome (MDS)
18. A Phase II Study of CCI-779 (Temsirolimus, Torisel) in Combination with Rituximab (Rituxan) in Patients with Relapsed or Refractory (Resistent) Mantle Cell Lymphoma
19. Phase II Study with Azacitidine with or without (the Histone Deacetylase Inhibitor) MS-275 for the Treatment of Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CML) and Acute Myeloid Leukemia (AML)
20. Treatment Study for Patients Diagnosed with High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
21. A Phase 3 Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
22. Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)
23. A Phase 3 Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Disease
24. AMG 531 for Myelodysplastic Syndrome (MDS) Patients Receiving Lenalidomide (Revlimid)
25. Phase 2 Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation
26. A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma [Diffuse Large B-Cell Lymphoma (DLBCL)] Using Daily Enzastaurin (LY317615.HCl)
27. Comparing the Effects of 3 Different Dosing Regimens of Epoetin Alfa, a Medicine Used to Treat Anemia, and a Dosing Schedule of Darbepoetin Alfa, a Different Medicine Used to Treat Anemia, in Patients Diagnosed with Cancer
28. A Phase 3 Study of Dose-intensive Response-based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease
29. A Phase 3 Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine
30. A Phase II Study of Sunitinib Malate (Sutent) for Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
31. Study of the Monoclonal Antibody, Bevacizumab (Avastin) and CHOP (A-CHOP) (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Combination for Patients with Lymphoma Types of Peripheral T-Cell or Natural Killer Cell Neoplasms
32. A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy
33. CNTO 328, A Phase 2 Multicenter Study of CNTO 328 (Anti IL- 6 Monoclonal Antibody) in Patients with Relapsed or Refractory (resistant) Multiple Myeloma
34. J0615, Phase II Trial of Rituximab (Rituxan)-ABVD for Classical Hodgkin Lymphoma
35. A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma
36. H23750, The Effect of Diflunisal (Dolobid) (IND 68092) On Familial Amyloidosis: A randomized, double blind, placebo controlled, international multi-center trial of Diflunisal on neurologic disease progression in 200 familial amyloidal patients
37. MC0686, A Phase II Trial of Cyclophosphamide (Cytoxan), Bortezomib (Velcade, PS-341), and Dexamethasone (CYBOR-D) in Patients with Newly Diagnosed Active Multiple Myeloma
38. N0682, A Phase II Study of Denileukin Diftitox in Combination with Rituximab (Rituxan) in Previously Untreated Follicular B-cell Non-Hodgkin Lymphoma Patients
39. C05008, Phase 1/2 Study of Velcade (Bortezomib, PS-341), Dexamethasone, and Revlimid (Lenalidomide) (VDR) versus Velcade, Dexamethasone, Cyclophosphamide (Cytoxan), and Revlimid (VDCR) versus VELCADE, Dexamethasone, and Cyclophosphamide (VDC) in Patients with Previously Untreated Multiple Myeloma
40. Combination Chemotherapy (Methotrexate, Nelarabine) in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
41. E1902, A Phase II Study of Reduced Intensity Allogeneic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes (MDS)
42. MC0784, Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (Rituxan) followed by Consolidation with Lenalidomide (Revlimid) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
43. MC0785, Antibody Therapy with Alemtuzumab (Campath), Rituximab (Rituxan), and GMCSF (Sargramostim) for Initial Treatment of High Risk Chronic Lymphocytic Leukemia (CLL)
44. Phase II Study of Rituximab (Rituxan) Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma
45. Phase 2 Study to Evaluate the Safety and Efficacy of Monoclonal Antibody Lumiliximab in Combination with Fludarabine, Cyclophosphamide (Cytoxan), and Rituximab (Rituxan) Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
46. Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome (MDS)
47. Randomized Phase III Clinical Trial Comparing Outcomes of Immunologic Autograft Engineering Versus Standard Autograft Collection in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma
48. A Phase I Study of Weekly Oral ZEN-012, a Small Molecule Anti-Cancer Agent, in Patients With Advanced Cancer and Lymphoma
49. A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
50. SG040-0005, A Randomized, Phase IIb Placebo-controlled Study of RICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
51. A Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory (Resistant) Multiple Myeloma
52. A Phase 2, Study of Carfilzomib in Patients with Relapsed Multiple Myeloma
53. A Phase II Trial of CC-4047 (Actimed) Plus Dexamethasone (Decadron) in Patients with Relapsed or Refractory (Resistant) Multiple Myeloma
54. Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
55. A Phase 2 Trial of Bevacizumab (Avastin) to Prevent or Delay Disease Progression in Patients with Relapsed/Refractory (Resistent) Chronic Lymphocytic Leukemia (CLL)
56. E1A05, Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®)-Lenalidomide (Revlimid®) -Dexamethasone (VRD) versus Bortezomib (Velcade®) - Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen
57. AAML0431, The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years
58. AHOD0521, A Phase II Study of Bortezomib (Velcade, PS-341, IND #58443) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults with Refractory/Recurrent Hodgkin Disease
59. Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
60. MC0788, "Phase II Trial of Low Dose Decitabine (Dacogen) in Patients with Primary Myelofibrosis and Post ET/PV Myelofibrosis"
61. Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia (ALL) That Has Relapsed in the Central Nervous System (CNS) or Testes
62. A Phase 2b Study of Molecular Responses to Imatinib (Gleevec) at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase
63. MC0482, Phase III Study of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL)
64. AALL06N1, "A Study of Neurocognitive Function in Children Treated for Acute Lymphocytic Leukemia (ALL)"
65. ADVL0525: Phase II Study of Pemetrexed (Alimta) in Children with Recurrent Malignancies (Cancer)
66. ACF4375g: An Open-Label, Phase 1b, Dose-Escalation Study of the Safety and Pharmacology of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination with Bortezomib (Velcade, PS-341) in Patients with Relapsed or Refractory (resistant) Multiple Myeloma
67. MC0687, A Phase II Study of Thymoglobulin and Melphalan in patients with Relapsed Multiple Myeloma
68. A Phase Ib Study of SGN-40 (anti-huCD40 mAb) in Combination with Rituximab (Rituxan) and Gemcitabine (Gemzar) for the Treatment of Patients with Relapsed or Refractory (resistant) Diffuse Large B Cell Lymphoma (DLBCL)
69. MF-TG101348-001, A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
70. MC078B, A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 (Actimed) in Patients with Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis
71. A Phase I Study of Weekly Oral ZEN-012, a Small Molecule Anti-Cancer Agent, in Patients With Advanced Cancer and Lymphoma
72. Rituxan in Hemophilia A Patients Who Have Antibodies to FVIII.